Amsurg Corp (AMSG) Tops Q1 EPS by 2c; Boosts FY12 Outlook, Guides Q2 EPS
Tweet
Share
E-mailGet Alerts AMSG Hot Sheet
Price: $67.75 --0%
Financial Fact:
Total operating expenses: 672.65M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Financial Fact:
Total operating expenses: 672.65M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Join SI Premium – FREE
Amsurg Corp (NASDAQ: AMSG) reported Q1 EPS of $0.50, $0.02 better than the analyst estimate of $0.48. Revenue for the quarter came in at $177.7 million versus the consensus estimate of $219.06 million.
Amsurg Corp sees Q2 2012 EPS of $0.49-$0.51, versus the consensus of $0.49.
Amsurg Corp sees FY2012 EPS of $1.97-$2.01, versus prior guidance of $1.95-$1.99 and the consensus of $1.98. Amsurg Corp sees FY2012 revenue of $905-$925 million, versus prior guidance of $900-$920 million and the consensus of $911.6 million.
For earnings history and earnings-related data on Amsurg Corp (AMSG) click here.
Amsurg Corp sees Q2 2012 EPS of $0.49-$0.51, versus the consensus of $0.49.
Amsurg Corp sees FY2012 EPS of $1.97-$2.01, versus prior guidance of $1.95-$1.99 and the consensus of $1.98. Amsurg Corp sees FY2012 revenue of $905-$925 million, versus prior guidance of $900-$920 million and the consensus of $911.6 million.
For earnings history and earnings-related data on Amsurg Corp (AMSG) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- Telesat Corporation (TSAT) Misses Q2 EPS by 1006c
- Ascendis Pharma (ASND) Tops Q2 EPS by 132c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
